Atrial fibrillation pregnancy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 48: Line 48:


4. Administration of [[quinidine]] or [[procainamide]] may be considered to achieve pharmacological [[cardioversion]] in hemodynamically stable patients who develop [[AF]] during pregnancy. ''(Level of Evidence: C)''}}
4. Administration of [[quinidine]] or [[procainamide]] may be considered to achieve pharmacological [[cardioversion]] in hemodynamically stable patients who develop [[AF]] during pregnancy. ''(Level of Evidence: C)''}}
==See Also==
* [[The Living Guidelines: Diagnosis and Management of Atrial Fibrillation | The AF Living Guidelines: Vote on current recommendations and suggest revisions to the guidelines]]


==Sources==
==Sources==

Revision as of 13:42, 17 June 2009

Conduction
Sinus rhythm
Atrial fibrillation
Atrihttp://miles.wikidoc.org/skins/common/images/button_bold.pngal fibrillation
The P waves, which represent depolarization of the atria, are irregular or absent during atrial fibrillation.
ICD-10 I48
ICD-9 427.31
DiseasesDB 1065
MedlinePlus 000184
eMedicine med/184  emerg/46

WikiDoc Resources for Atrial fibrillation pregnancy

Articles

Most recent articles on Atrial fibrillation pregnancy

Most cited articles on Atrial fibrillation pregnancy

Review articles on Atrial fibrillation pregnancy

Articles on Atrial fibrillation pregnancy in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Atrial fibrillation pregnancy

Images of Atrial fibrillation pregnancy

Photos of Atrial fibrillation pregnancy

Podcasts & MP3s on Atrial fibrillation pregnancy

Videos on Atrial fibrillation pregnancy

Evidence Based Medicine

Cochrane Collaboration on Atrial fibrillation pregnancy

Bandolier on Atrial fibrillation pregnancy

TRIP on Atrial fibrillation pregnancy

Clinical Trials

Ongoing Trials on Atrial fibrillation pregnancy at Clinical Trials.gov

Trial results on Atrial fibrillation pregnancy

Clinical Trials on Atrial fibrillation pregnancy at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Atrial fibrillation pregnancy

NICE Guidance on Atrial fibrillation pregnancy

NHS PRODIGY Guidance

FDA on Atrial fibrillation pregnancy

CDC on Atrial fibrillation pregnancy

Books

Books on Atrial fibrillation pregnancy

News

Atrial fibrillation pregnancy in the news

Be alerted to news on Atrial fibrillation pregnancy

News trends on Atrial fibrillation pregnancy

Commentary

Blogs on Atrial fibrillation pregnancy

Definitions

Definitions of Atrial fibrillation pregnancy

Patient Resources / Community

Patient resources on Atrial fibrillation pregnancy

Discussion groups on Atrial fibrillation pregnancy

Patient Handouts on Atrial fibrillation pregnancy

Directions to Hospitals Treating Atrial fibrillation pregnancy

Risk calculators and risk factors for Atrial fibrillation pregnancy

Healthcare Provider Resources

Symptoms of Atrial fibrillation pregnancy

Causes & Risk Factors for Atrial fibrillation pregnancy

Diagnostic studies for Atrial fibrillation pregnancy

Treatment of Atrial fibrillation pregnancy

Continuing Medical Education (CME)

CME Programs on Atrial fibrillation pregnancy

International

Atrial fibrillation pregnancy en Espanol

Atrial fibrillation pregnancy en Francais

Business

Atrial fibrillation pregnancy in the Marketplace

Patents on Atrial fibrillation pregnancy

Experimental / Informatics

List of terms related to Atrial fibrillation pregnancy

Cardiology Network

Discuss Atrial fibrillation pregnancy further in the WikiDoc Cardiology Network
Adult Congenital
Biomarkers
Cardiac Rehabilitation
Congestive Heart Failure
CT Angiography
Echocardiography
Electrophysiology
Cardiology General
Genetics
Health Economics
Hypertension
Interventional Cardiology
MRI
Nuclear Cardiology
Peripheral Arterial Disease
Prevention
Public Policy
Pulmonary Embolism
Stable Angina
Valvular Heart Disease
Vascular Medicine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Synonyms and related keywords: AF, Afib, fib

Overview

ACC / AHA Guidelines- Pregnancy (DO NOT EDIT) [1]

Class I

1. Digoxin, a beta blocker, or a non dihydropyridine calcium channel antagonist is recommended to control the rate of ventricular response in pregnant patients with AF. (Level of Evidence: C)

2. Direct-current cardioversion is recommended in pregnant patients who become hemodynamically unstable due to AF. (Level of Evidence: C)

3. Protection against thromboembolism is recommended throughout pregnancy for all patients with AF (except those with lone AF and/or low thromboembolic risk). Therapy (anticoagulant or aspirin) should be chosen according to the stage of pregnancy. (Level of Evidence: C)

Class IIb

1. Administration of heparin may be considered during the first trimester and last month of pregnancy for patients with AF and risk factors for thromboembolism. Unfractionated heparin may be administered either by continuous intravenous infusion in a dose sufficient to prolong the activated partial thromboplastin time to 1.5 to 2 times the control value or by intermittent subcutaneous injection in a dose of 10 000 to 20 000 units every 12 h, adjusted to prolong the mid-interval (6 h after injection) activated partial thromboplastin time to 1.5 times control. (Level of Evidence: B)

2. Despite the limited data available, subcutaneous administration of low molecular weight heparin may be considered during the first trimester and last month of pregnancy for patients with AF and risk factors for thromboembolism. (Level of Evidence: C)

3. Administration of an oral anticoagulant may be considered during the second trimester for pregnant patients with AF at high thromboembolic risk. (Level of Evidence: C)

4. Administration of quinidine or procainamide may be considered to achieve pharmacological cardioversion in hemodynamically stable patients who develop AF during pregnancy. (Level of Evidence: C)

See Also

Sources

  • The ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation [1]

References

  1. 1.0 1.1 Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation- Executive Summary: executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidlines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114: 700-752. PMID 16908781

Further Readings

  • Fuster V, Rydén LE, Cannom DS, et al (2006). "ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society". Circulation 114 (7): e257-354. doi:10.1161/CIRCULATIONAHA.106.177292. PMID 16908781.
  • Estes NAM 3rd, Halperin JL, Calkins H, Ezekowitz MD, Gitman P, Go AS, McNamara RL, Messer JV, Ritchie JL, Romeo SJW, Waldo AL, Wyse DG. ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with non valvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Performance Measures for Atrial Fibrillation). Circulation 2008; 117:1101–1120

Template:SIB

de:Vorhofflimmern it:Fibrillazione atriale nl:Boezemfibrilleren no:Atrieflimmer fi:Eteisvärinä


Template:WikiDoc Sources